Chapter 1
When Science Betrays: The Alzheimer's Deception
In the quiet corridors of research labs across America, a devastating fraud has unfolded-one that has cost billions in wasted resources and delayed hope for millions suffering from one of humanity's most terrible afflictions. Charles Piller's "Doctored" pulls back the curtain on how the quest to understand and treat Alzheimer's disease became corrupted by fabricated data, conflicts of interest, and institutional failures. The book has become required reading in medical ethics courses at Harvard and Stanford, with Bill Gates calling it "a wake-up call for how we fund and evaluate scientific research." The investigation began with a single whistleblower's discovery but expanded into a shocking expose of how the dominant theory of Alzheimer's disease-the amyloid hypothesis-has been propped up by questionable research while alternative approaches were systematically sidelined. As we face an aging population with Alzheimer's cases projected to triple by 2050, this scientific scandal carries implications far beyond academia.
Chapter 2
The Price of Hope: A Family's Alzheimer's Journey
Stephen Price, a 74-year-old retired construction contractor from rural New Jersey, is losing himself piece by piece to Alzheimer's disease. Six years into his diagnosis, he enrolled in a clinical trial for simufilam, an experimental drug that promised not just to slow his decline but potentially reverse it-a holy grail in Alzheimer's treatment. His son Matt, a Harvard-trained epidemiologist, accompanies him to appointments, watching with scientific understanding and personal heartbreak as his father struggles with daily tasks that once came naturally.
"I have to handle things differently," Stephen explains, describing how interruptions now derail his thoughts completely. His wife Toni has adapted their home and routines to accommodate his changing abilities, while living with the knowledge that Stephen carries two copies of the APOE4 gene-dramatically increasing not only his Alzheimer's risk but potentially his children's as well.
This genetic reality drives Stephen's participation in clinical trials. "He's doing it for society," Matt explains, "and for future patients who might include his own children." Before simufilam, Stephen had participated in a psilocybin trial at Johns Hopkins that temporarily helped him accept his illness and alleviated his depression when conventional medications failed. Matt described it as "among the most meaningful experiences" in his father's life.
Simufilam offered an entirely different kind of hope. The drug supposedly repairs filamin A, a brain protein that can block amyloid-beta plaques-widely considered hallmarks of Alzheimer's disease. If successful, it might slow or even reverse Stephen's cognitive decline, allowing him to recapture aspects of himself that were slipping away.
But as months passed in the trial, Stephen's condition continued deteriorating. After eighteen months, he struggled with basic cognitive tasks-remembering simple words, drawing shapes, recalling the day or his location. Though he maintained some routines like Tai Chi, his independence was rapidly diminishing. Sometimes he looked confused about which end of a fork to hold. The family continued supporting his independence while recognizing the painful reality that "what's possible for him is shrinking." The evidence was clear: Alzheimer's was winning, and simufilam was failing.
Chapter 3
The Unlikely Whistleblower: Matthew Schrag's Journey
In his modest Vanderbilt University office, neurologist and neuroscientist Matthew Schrag maintains a small medical museum of antique reflex hammers, medical manuals, and an old microscope-tributes to medicine's long history of scientific inquiry. A sign on his desk declares "Everything Is Figureoutable," though Alzheimer's disease has thus far defied this optimistic motto. This personal collection reflects not just his passion for medical history, but his belief in the methodical progression of scientific understanding.
Unlike many elite researchers, Schrag's scientific journey began humbly at the University of North Dakota-a stark contrast to the Harvard pedigrees common in his field. Under neuropharmacologist Othman Ghribi, he learned western blot analysis-a technique that separates proteins by size to reveal their presence in tissue samples. This seemingly technical skill would later prove crucial in his scientific investigations. During these formative years, Schrag developed a meticulous attention to detail and a fundamental understanding of protein analysis that would set him apart from his peers.
After completing his rigorous training at Yale, where he further honed his expertise in neurodegenerative diseases, Schrag established himself at Vanderbilt in 2015. There, he focused on cerebral amyloid angiopathy (CAA)-a condition where amyloid plaques attack blood vessels in the brain and which affects approximately 85-95% of Alzheimer's patients. His lab features striking fluorescent images of diseased brain tissue, displaying what he calls "great beauty within disease and death." Through thousands of hours examining western blots and microscopic images, Schrag developed an intimate understanding of what scientific data should look like, including subtle patterns and irregularities that others might miss.
Despite the scientific community's long-held belief that science "self-corrects," Schrag recognized a troubling reality: revolutionary but false findings can persist for years without proper scrutiny, leading to wasted resources and even human suffering. He observed how the academic system actively disincentivizes replication efforts, as "negative results" are difficult to publish and can damage a researcher's career prospects. This systemic flaw particularly concerned him in Alzheimer's research, where billions of dollars and countless patient hopes hung in the balance.
When approached about investigating Cassava Sciences' simufilam research in 2021, Schrag immediately spotted suspect images but worried about career consequences. The irregularities he noticed included duplicated gel bands and manipulated images that suggested data manipulation. Despite the modest $18,000 payment and significant personal risk to his career and reputation, he ultimately felt compelled to act because a drug seemingly based on misconduct was being administered to hundreds of Alzheimer's patients in clinical trials.
"This is my scientific space," he explained when asked why he'd blown the whistle, adding that his position as an Alzheimer's researcher gave him both the expertise and moral obligation to speak up. "The most important thing is that we get all of this right because many people's lives depend on it." His decision to come forward would not only challenge a billion-dollar pharmaceutical company but also spark a broader conversation about scientific integrity in Alzheimer's research.
Chapter 4
The Olympic Scientist: Lindsay Burns and Cassava Sciences
Lindsay Burns emerged from the remote ranchlands of Big Timber, Montana with exceptional drive and talent. Born to a family that balanced western ranching heritage with East Coast education, Burns showed competitive spirit from an early age-winning local sack races at seven and conducting tree surveys at ten. Following family tradition, she attended Milton Academy and then Harvard, where she excelled in both psychobiology and rowing.
Despite her lightweight status (under 130 pounds), Burns showed extraordinary determination in rowing-competing through a cracked rib, practicing on weekends by scaling the boathouse walls, and eventually winning a silver medal at the 1996 Atlanta Olympics. Her hometown celebrated with "Lindsay Burns Day," honoring her unbridled determination and competitive drive that would later characterize her scientific work.
After her Olympic success, Burns turned to drug development, joining Pain Therapeutics in 2002. Led by CEO Remi Barbier (whom she later married), the company focused on developing "Remoxy," an abuse-deterrent oxycodone formulation. Burns formed a crucial research partnership with Hoau-Yan Wang, a CUNY professor with expertise in brain dopamine receptors. Together, they focused on filamin A, a brain protein affecting opioid receptors, ultimately sharing fourteen patents.
When Pain Therapeutics faced failure after the FDA repeatedly rejected Remoxy, Barbier desperately needed a new direction. Wang and Burns provided it: repurposing their filamin A research for Alzheimer's disease. While most experts believe Alzheimer's involves tau tangles inside neurons and amyloid-beta plaques between cells, Wang and Burns proposed a novel hypothesis-claiming misfolded filamin A causes inflammation and promotes formation of these problematic proteins.
Barbier quickly pivoted, renaming the company "Cassava Sciences"-oddly chosen from the street where he and Burns lived, despite cassava root being falsely touted as a brain-health remedy while some varieties actually contain cyanide.
Wang's research methods bordered on the fantastical. He claimed to revivify frozen brain tissue-some preserved for years-to test simufilam's effects. This "zombie science" supposedly showed the drug countering Alzheimer's by addressing insulin resistance in the brain. Respected scientists found the claims implausible-"It's hard for me to imagine how you could get any life from that tissue," noted UCSF's Roger Nicoll. Yet Wang attracted elite coauthors from institutions like Harvard and Rush University, lending credibility to his work.
When Cassava's early clinical trial of simufilam initially failed, with the drug showing no reduction in tau or other Alzheimer's biomarkers, the stock plummeted 75% overnight. Months later, Barbier blamed "mistakes" by a lab contractor and announced a miraculous turnaround-not only had biomarkers improved, but patients showed memory improvements after just one month. The company's market value skyrocketed to $5.4 billion, making the Barbier-Burns family worth $147 million on paper.
Chapter 5
The French Connection: Sylvain Lesne's Rise and Fall
In France's coastal Luc-sur-Mer, Sylvain Lesne grew up amid D-Day history, developing both ambition and a gambling spirit reflected in the town's casino culture. Handsome, athletic, and fluent in English, Lesne became a popular ambassador for Alzheimer's research while his graduate work garnered over a thousand citations-extraordinary early influence.
Twenty years before the scandal broke, Denis Vivien, one of Lesne's PhD advisors, discovered troubling evidence when Lesne submitted immunostaining images that looked "too beautiful" to be real. When another student couldn't replicate Lesne's findings, Vivien confronted him. Despite Lesne's denial of wrongdoing, Vivien withdrew the paper before publication "to preserve my scientific integrity" and severed contact with Lesne.
Though Vivien implemented lab audit systems afterward, he never warned the wider scientific community or Lesne's other mentors. Without speaking to anyone from Caen, Karen Ashe, an illustrious Alzheimer's researcher at the University of Minnesota, hired Lesne as a postdoctoral fellow in 2002-a decision that would later profoundly impact both their careers and Alzheimer's research itself.
Ashe, born to high-achieving Chinese immigrants, had an extraordinary pedigree-graduating from Harvard at 17 and completing both an MD and PhD within a decade. Her scientific brilliance was evident early, from her childhood brain-shaped school project to becoming the first Asian American at St. Paul Academy. Ashe's groundbreaking work with Stanley Prusiner on prions contributed to his Nobel Prize, and her development of transgenic mice that produced human amyloid proteins revolutionized Alzheimer's research.
The synergy between Ashe's scientific genius and Lesne's experimental prowess proved electric-she recognized his talent for isolating amyloid oligomers and promoted him as "brilliant." Together they achieved remarkable breakthroughs, including Ashe's stunning discovery that mice could actually recover memory after tau protein production was halted.
Then came the breathtaking moment that captured the field's imagination: Ashe and Lesne discovered A*56, a previously unknown amyloid-beta oligomer. When purified from mouse brains and injected into rats, it instantly impaired their memory. Published in Nature, the finding was hailed as "the first substance ever identified in brain tissue in Alzheimer's research that has been shown to cause memory impairment." The discovery provided crucial support for the amyloid hypothesis when skepticism was mounting.
Leading experts called it "clearly a key finding," while Sam Gandy predicted it would become "the target" for research. Less than two weeks after publication, Ashe won the $100,000 Potamkin Prize, and later received a $5 million donation for her research center. Lesne was promoted to assistant professor with his own NIH-funded lab.
Chapter 6
The Amyloid Mafia: How a Hypothesis Became Dogma
In November 2022, Harvard professor Dennis Selkoe, one of the most celebrated Alzheimer's researchers, confronted Piller over lunch about media pessimism regarding anti-amyloid drugs. With remarkable verbal acumen and persuasiveness, Selkoe claimed to be "on the right side of history," noting he had waited decades for "objective evidence" that reducing amyloid improves cognitive outcomes.
The "amyloid mafia" describes influential figures who steer funding and opportunities toward the amyloid hypothesis while marginalizing alternatives. Former NIH director Zaven Khachaturian called it "an infallible belief system" where scientists "accept an idea as infallible." Following the 2006 Lesne-Ashe paper in Nature, NIH funding for oligomer research exploded from nearly zero to $333 million by 2021, with amyloid-related projects receiving $1.5 billion of the $3 billion Alzheimer's budget.
Despite authoring over 1,100 scholarly articles cited more than 75,000 times, George Perry, editor of the Journal of Alzheimer's Disease and a prominent skeptic of the amyloid hypothesis, hasn't been invited to speak at major Alzheimer's conferences in recent years. Many scientists describe career obstacles when challenging the dominant theory. One researcher received whispered advice to at least pretend her work linked to amyloids in grant proposals. Others found venture capitalists and pharmaceutical companies would only back anti-amyloid approaches.
NIH program officers recommended including "pro-amyloid collaborators" in applications, while alternative theories faced publication rejections from top journals. Scientists like Ruth Itzhaki, Robert Moir, and Malu Tansey struggled for funding and recognition when proposing alternative explanations involving herpes virus, microbial causes, or immune responses.
Perry believes the amyloid hypothesis persists because its champions seek legacy and recognition: "The major goal of these people is to win-if it isn't the Nobel Prize, it's God's glory." He argues funders favor established amyloid researchers like Selkoe because they're "safe" investments who publish in prestigious journals, creating an avalanche of amyloid-related papers that crowds out alternative approaches.
The hypothesis has survived through constant evolution-being called the "amyloid plaque," "amyloid-beta," "amyloid cascade," and "amyloid oligomer" hypotheses-making it, as Stanford's Sudhof notes, impossible to disprove.
Chapter 7
Blots on a Field: Uncovering Scientific Fraud
In December 2021, Matthew Schrag was developing techniques to quantify image manipulation in scientific papers when he found a paper in the Journal of Neuroscience with suspicious western blots that looked like "flat-bottom smiles." Using NIH-approved software, he colored one band red and another green, then merged them to reveal a perfect match (shown in yellow), with a correlation coefficient of 0.98-virtually identical bands that should represent different experimental conditions.
Following this thread, Schrag discovered these manipulations led to Sylvain Lesne at the University of Minnesota, whose name appeared on multiple papers with similar issues. His investigation quickly expanded as he found questionable images in multiple prestigious journals. Most significantly, Schrag discovered problems in Lesne's seminal 2006 Nature paper, co-authored with Karen Ashe, which had introduced amyloid-beta star 56 (A*56) and been cited thousands of times.
This paper had reinvigorated the amyloid hypothesis at a moment of despair in the field, redirecting research toward oligomers and away from plaques. If Schrag's suspicions were correct, a key advance in Alzheimer's research was built on fabricated results, potentially undermining the dominant approach to curing the disease.
Schrag's findings received powerful validation from leading forensic image analysts. Elisabeth Bik confirmed his concerns that research groups appeared to have composed figures by piecing together parts from different experiments, suggesting data might have been altered to fit hypotheses. Jana Christopher also endorsed Schrag's work, even identifying additional cloned image sections he had missed.
Dennis Selkoe served as Piller's "acid test" for evaluating Lesne's apparent misconduct. After reviewing Schrag's dossier, Selkoe confirmed at least "twelve or fifteen images where there is no other explanation" than manipulation, particularly in the landmark 2006 Nature paper. He noted that Lesne's unique system for measuring amyloid-beta oligomers separately in different cellular compartments "made no biochemical sense" to experienced researchers.
Despite numerous publications by Lesne and Karen Ashe on A*56, few labs ever successfully detected the protein, with many failing in unpublished attempts. Selkoe worried about the impact of exposing this misconduct on public trust in science, especially after attacks on scientists during the Trump presidency and Covid pandemic, but ultimately concluded: "We need to declare these examples and warn the world."
By enhancing contrast on published images, Schrag revealed obvious signs of digital manipulation in the 2006 Nature paper, including use of eraser tools that deleted evidence contradicting assertions about purified A*56. These findings ultimately led to the paper's retraction in 2024, with Ashe and most co-authors acknowledging image doctoring had occurred (only Lesne disagreed).
Chapter 8
Systemic Failure: How Institutions Protected Fraud
The investigation into scientific integrity revealed shocking findings about Eliezer Masliah, director of the NIA Division of Neuroscience and one of the world's most powerful Alzheimer's scientists with a $2.6 billion annual budget. A 300-page dossier compiled by researchers identified 132 apparently doctored papers by Masliah-the most for any scientist examined-showing questionable western blots, micrographs, and reused images dating back to 1997.
Eleven leading neuroscientists who reviewed the dossier were stunned, with one calling the findings "breathtaking." The questionable research included studies that helped win FDA approval for clinical trials of prasinezumab, a Parkinson's drug that showed no benefit in a recent trial. Masliah's dubious work raises serious questions about the vetting process at NIH, which acknowledged his work was not checked for possible fraud before hiring.
When NIH receives misconduct concerns, it conducts preliminary reviews before passing credible cases to the Office of Research Integrity (ORI). However, this process is plagued by delays and opacity. Despite Schrag submitting his Cassava dossier in 2021 and Lesne dossier in 2022, he received no response. Meanwhile, NIH continued funding Lesne's work for five more years, even though the administrator overseeing the grant had co-authored Lesne's suspect 2006 Nature paper.
ORI's meager resources-just 37 employees and a $12 million budget to oversee $48 billion in NIH funding-contribute to this ineffectiveness. Universities typically conduct investigations themselves, often gaining extensions that drag cases out indefinitely, with few researchers ever facing penalties for misconduct.
The FDA's oversight of clinical trials shows similar weaknesses. A 2020 investigation revealed a light-handed, slow-moving approach to violations, with clear corrections of dangerous practices being rare. The FDA typically requests voluntary corrections rather than taking decisive action, and participants in compromised trials often aren't notified of problems.
Critics point to the "revolving door" between the FDA and industry-many senior officials, including Commissioners Rob Califf and Scott Gottlieb, had significant industry ties before or after their FDA tenure. A study found that eleven of sixteen FDA medical examiners who worked on twenty-eight drug approvals later became employees or consultants for the companies they regulated.
The Aduhelm approval exemplifies how corporate influence can compromise FDA oversight. Biogen donated heavily to patient advocacy groups that pressured the FDA, while maintaining a cozy relationship with the agency. Billy Dunn, the FDA's top regulator for Alzheimer's drugs, worked closely with Biogen through back channels to secure approval. After shepherding both Aduhelm and its successor Leqembi through approval, Dunn left the FDA to become an industry consultant and join the board of Prothena, an anti-amyloid biopharma company, receiving options for 30,000 shares.
Chapter 9
The Path Forward: Innovation and Hope
Despite the dominance of the amyloid hypothesis, alternative approaches are gaining traction. Madhav Thambisetty takes an innovative approach by comparing brain tissues from younger adults with and without Alzheimer's risk factors to tissues from deceased patients. Rather than developing entirely new drugs through costly decades-long trials, he searches for already-approved compounds that might be repurposed to target the abnormalities he identifies.
Another radical researcher, Ruth Itzhaki of Oxford, has spent decades investigating links between herpesvirus and Alzheimer's. After years of being marginalized, her infection hypothesis is finally gaining traction with NIH funding jumping to nearly $250 million annually in 2023, with clinical trial results expected by 2026.
Prevention offers a bridge from today's difficult reality to future effective treatments. Miguel Arce Renteria focuses on how better treatment systems can forestall Alzheimer's, particularly for Latino Americans who are 1.5 times more likely to develop the disease than whites, and African Americans who suffer at twice the rate. Risk factors like diabetes, high blood pressure, cholesterol, obesity, depression, hearing loss, sedentary lifestyles, and poor diets can be targeted to forestall or moderate Alzheimer's.
"Cognitive reserve" can help people function longer despite increasing brain pathology. Higher education can be protective, while poor childhood education increases risk. Though Alzheimer's can afflict anyone, it's also a disease of inequality.
In 2024, Matthew Schrag's lab produced 3D animations showing how cerebral amyloid angiopathy (CAA) transforms elegant networks of brain capillaries into gnarly, misshapen tubes with bulbous growths that eventually burst. Schrag believes few diseases of aging have just one cause-if they did, they would appear earlier and more consistently.
"It's time for the field to move on," he says, noting many scientists privately want to move past the amyloid hypothesis. Schrag studies inflammation in the brain, blood vessels that do "more than simple plumbing," and lysosomes-cellular structures that digest waste products. He sees hope in the concept that neurodegenerative diseases might be "age-related, lysosomal-storage diseases" that could respond to therapies enhancing lysosomal function.
Beyond his research, Schrag treats about 200 Alzheimer's patients yearly, helping them preserve dignity while accepting new realities. He emphasizes the importance of planning transitions like giving up driving or moving to assisted living before crises occur, allowing patients to maintain agency in their own lives.
In early 2024, Stephen Price continues his decline despite taking Cassava's simufilam in a clinical trial. His condition has worsened dramatically-he rarely speaks in complete sentences, struggles with basic functions like eating and toileting, and has wandered off dangerously. His wife Toni, 75, recently suffered a minor heart attack that Matt attributes to caregiving stress.
Matt feels ethically compromised by enabling his father's continued participation in the trial, especially after learning more about simufilam's scientific problems and the fraud indictment against one of its developers. The experience has taught Matt painful lessons about medical trust and time's preciousness, as he reluctantly explores nursing home options for his father whose agency diminishes daily.
Despite the scientific betrayals documented throughout "Doctored," the book ultimately offers hope that by exposing fraud and embracing diverse research approaches, we might finally make meaningful progress against this devastating disease that affects millions worldwide.
